European cannabis firms look to list in the US as it mulls easing controls

Cannabis could be moved from the stringent Schedule 1 classification of the Controlled Substances Act (CSA) to the relatively less regulated Schedule 3, in view of its medicinal and pharmaceutical properties and usages.

Several European cannabis start-ups are considering listing in New York as the Federal authorities propose to declassify marijuana as a less dangerous drug. 

This mainly involves companies who have still not made a concrete decision about when and where to list, but are being increasingly attracted by what they see as a more welcoming approach to marijuana and cannabidiol (CBD) products generally in the US. 

According to Statista, the value of the CBD products market could reach around $6.90 billion (€6.32 billion) this year.